Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 379, Issue 4, pp 379–384 | Cite as

Phosphodiesterases PDE3 and PDE4 jointly control the inotropic effects but not chronotropic effects of (−)-CGP12177 despite PDE4-evoked sinoatrial bradycardia in rat atrium

  • Alejandro Galindo-Tovar
  • Maria Luisa Vargas
  • Alberto J. Kaumann
Short Communication
First Online:
Received:
Accepted:

Abstract

Acting through a low-affinity site of the β1-adrenoceptor (β1LAR), CGP12177 causes sinoatrial tachycardia and positive inotropic effects in left atrium but not in the ventricle of the rat. However, inhibition of either PDE3 or PDE4 also uncovers positive inotropic effects of CGP12177 in ventricle, but whether these phosphodiesterases also control the atrial agonist effects of CGP12177 was unknown. We, therefore, investigated the effects of the PDE3-selective inhibitor cilostamide (300 nM) and PDE4 inhibitor rolipram (1 µM) on the (−)-CGP12177-evoked increases of sinoatrial beating rate and force of paced left atria of the rat. Rolipram (n = 8) increased basal sinoatrial rate by 27 ± 5 bpm but cilostamide (n = 8) had no effect. The chronotropic potency of (−)-CGP12177 (−logEC50M = 7.5) was not changed by rolipram and cilostamide or their combination. (-)-CGP12177 increased left atrial force with intrinsic activity 0.25 compared to (-)-isoprenaline. Rolipram (n = 8) and cilostamide (n = 8) did not change basal force of left atria but concurrent rolipram + cilostamide (n = 8) increased force by 52 ± 9% of the effect of 200 µM (−)-isoprenaline. Neither rolipram nor cilostamide affected the inotropic potency of (−)-CGP12177 (−logEC50M = 7.4) but concurrent rolipram + cilostamide caused potentiation (−logEC50M = 8.2) and converted (-)-CGP12177 into a full agonist compared to (-)-isoprenaline. Cyclic AMP appears to maintain sinoatrial rate and PDE4 elicits bradycardia through hydrolysis of cAMP in a compartment distinct from the β1LAR-induced cAMP compartment through which (−)-CGP12177 causes tachycardia. In contrast to the (−)-CGP12177-evoked tachycardia, not controlled by PDE3 and PDE4, these isoenzymes jointly reduce (−)-CGP12177-evoked increases of left atrial contractility through β1LAR.

Keywords

Rat atrial β1-adrenoceptors (−)-CGP12177 Sinoatrial tachycardia Cilostamide and rolipram Contractile force Phosphodiesterases PDE3 and PDE4 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

This work was supported by grant PI052338 Fondo Investigación Sanitaria of the Ministerio de Sanidad y Consumo, and the Séneca Foundation, of Spain.

References

  1. Baker JG, Hall IP, Hill SJ (2003) Agonist actions of “β-blockers” provide evidence for two agonist activation sites or conformations of the human β1-adrenoceptor. Mol Pharmacol 63:1312–1321PubMedCrossRefGoogle Scholar
  2. Barbuti A, DiFrancesco D (2008) Control of cardiac rate by “funny” channels in health and disease. Ann N Y Acad Sci 1123:213–233PubMedCrossRefGoogle Scholar
  3. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488–520PubMedCrossRefGoogle Scholar
  4. Christ T, Engel A, Ravens U, Kaumann AJ (2006) Cilostamide potentiates more the positive inotropic effects of (−)-adrenaline through β2-adrenoceptors than the effects of (−)-noradrenaline through β1-adrenoceptors in human atrial myocardium. Naunyn-Schmiedeberg’s Arch Pharmacol 374:249–253CrossRefGoogle Scholar
  5. Christ T, Galindo-Tovar A, Thoms M, Ravens U, Kaumann AJ (2009) Inotropy and L-type Ca2+ current, activated by β1- and β2-adrenoceptors, are differently controlled by phosphodiesterases3 and 4 controlled in rat heart. Br J Pharmacol (in press)Google Scholar
  6. DiFrancesco D, Tortora P (1991) Direct activation of cardiac pacemaker channels by intracellular cyclic AMP. Nature 351:145–147PubMedCrossRefGoogle Scholar
  7. Galindo-Tovar A, Kaumann AJ (2008) Phosphodiesterase4 blunts inotropism and arrhythmias but not sinoatrial tachycardia of (−)-adrenaline mediated through mouse cardiac β1-adrenoceptors. Br J Pharmacol 153:710–720PubMedCrossRefGoogle Scholar
  8. Galindo-Tovar A, Vargas ML, Escudero E, Kaumann AJ (2009) Ontogenic changes of the control by phosphodiesterase3 and 4 of 5-HT responses in porcine heart and relevance to human atrial 5-HT4 receptors. Br J Pharmacol (in press)Google Scholar
  9. Joseph SS, Lynham JA, Colledge WH, Kaumann AJ (2004) Binding of (−)-[3H]-CGP12177 at two sites in recombinant human β1-adrenoceptors and interaction with β-blockers. Naunyn-Schmiedeberg’s Arch Pharmacol 369:525–532CrossRefGoogle Scholar
  10. Kaumann AJ (1996) (−)-CGP 12177-induced increase of human atrial contraction through a putative third β-adrenoceptor. Br J Pharmacol 117:93–98PubMedGoogle Scholar
  11. Kaumann AJ, Lynham JA (1997) Stimulation of cyclic AMP-dependent protein kinase in rat atria by (−)-CGP12177 through an atypical β-adrenoceptor. Br J Pharmacol 120:187–189CrossRefGoogle Scholar
  12. Kaumann AJ, Molenaar P (1996) Differences between the third β-adrenoceptor and the colonic β3-adrenoceptor in the rat. Br J Pharmacol 118:2085–2098PubMedGoogle Scholar
  13. Kaumann AJ, Molenaar P (2008) The low-affinity site of the β1-adrenoceptor and its relevance to cardiovascular pharmacology. Pharmacol Ther 118:303–336PubMedCrossRefGoogle Scholar
  14. Kaumann AJ, Semmler AL, Molenaar P (2007) The effects of both noradrenaline and CGP12177, mediated through human β1-adrenoceptors, are reduced by PDE3 in human atrium but PDE4 in CHO cells. Naunyn-Schmiedeberg’s Arch Pharmacol 375:123–131CrossRefGoogle Scholar
  15. Lowe MD, Lynham JA, Grace AA, Kaumann AJ (2002) Comparison of the affinity of β-blockers for two states of the β1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol 135:451–461PubMedCrossRefGoogle Scholar
  16. Rochais F, Abi-Gerges A, Horner K, Lefebvre F, Cooper MF, Conti M, Fischmeister R, Vandecasteele G (2006) A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular mytocytes. Circ Res 98:1081–1088PubMedCrossRefGoogle Scholar
  17. Sarsero D, Molenaar P, Kaumann AJ, Freestone NS (1999) Putative β4-adrenoceptors in rat ventricle mediate increases in contractile force and cell Ca2+: comparison with atrial receptors and relationship to (−)-[3H]-(−)-CGP 12177 binding. Br J Pharmacol 128:1445–1460PubMedCrossRefGoogle Scholar
  18. Smith CJ, Vasta V, Degerman E, Belfrage P, Manganiello VC (1991) Hormone sensitive cyclic GMP-inhibited cyclic AMP phosphodiesterases in rat adipocytes. J Biol Chem 266:13385–13390PubMedGoogle Scholar
  19. Vargas ML, Hernandez J, Kaumann AJ (2006) Phosphodiesterase PDE3 blunts the positive inotropic and cyclic AMP enhancing effects of CGP12177 but not of noradrenaline in rat ventricle. Br J Pharmacol 147:158–163PubMedCrossRefGoogle Scholar
  20. Vinogradova TM, Lyashkov AE, Zhu W, Ruknudin AM, Sirenko S, Yang D, Deo S, Barlow M, Johnson S, Caffrey JL, Zhou Y-Y, Xiao R-P, Cheng H, Stern MD, Maltsev VA, Lakatta EG (2006) High basal protein kinase A-dependent phosphorylation drives rhythmic internal Ca2+ store oscillations and spontaneous beating of cardiac pacemaker cells. Circ Res 98:505–514PubMedCrossRefGoogle Scholar
  21. Vinogradova TM, Sirenko S, Lyashkov AE, Younes A, Li Y, Zhu W, Yang D, Ruknudin AM, Spurgeon H, Lakatta EG (2008) Constitutive phosphodiesterase activity restricts spontaneous beating rate of cardiac pacemaker cells by suppressing local Ca2+ releases. Circ Res 102:761–769PubMedCrossRefGoogle Scholar
  22. Younes A, Lyashkov AE, Graham D, Sheydina A, Volkova MV, Vinogradova TM, Lukyanenko YO, Li Y, Ruknudin AM, Boheler KR, Van Eyk J, Lakatta EG (2008) Ca2+-stimulated basal adenylyl cyclase activity localization in membrane lipid microdomains of cardiac sinoatrial nodal pacemaker cells. J Biol Chem 283:14461–14468PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Alejandro Galindo-Tovar
    • 1
  • Maria Luisa Vargas
    • 1
  • Alberto J. Kaumann
    • 2
  1. 1.Department of PharmacologyUniversity of Murcia and Research Unit of the University Hospital Virgen de la ArrixacaMurciaSpain
  2. 2.Department of Physiology, Development and NeuroscienceCambridge UniversityCambridgeUK

Personalised recommendations